In late March the pivot of ASX small-cap Cellmid into the fight against COVID-19 raised a few eyebrows given the loss-making company's core business is selling always reliable anti-ageing and hair-loss prevention products.

Since then, Cellmid has raised a total of $6.3 million at 22¢ a share from investors to purchase COVID-19 antibody testing kits from Chinese manufacturer Wondfo. It's already had 12,000 of the tests imported into Australia and reports that they were approved for inclusion on the Therapeutic Goods Administration's (TGA) regulatory register on March 25.